Tert-butyl 2,2-dimethyl-4-prop-1-ynyl-1,3-oxazolidine-3-carboxylate | 1087044-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: Tert-butyl 2,2-dimethyl-4-prop-1-ynyl-1,3-oxazolidine-3-carboxylate
• CAS: 1087044-00-5
• 化学式: C₁₃H₂₁NO₃
• 分子量: 239.315
• InChiKey: DNAALPJCHQFUGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Tert-butyl 2,2-dimethyl-4-prop-1-ynyl-1,3-oxazolidine-3-carboxylate 在 三氟乙酸 作用下， 以 甲醇 为溶剂， 生成 tert-butyl N-(1-hydroxypent-3-yn-2-yl)carbamate
  参考文献：
  名称：

  Rhodium(I)-Catalyzed Cycloisomerization Reaction of Yne-Allenamides: An Approach to Cyclic Enamides

  摘要：

  在本文中，我们展示了通过铑（I）催化的环异构化反应将炔基烯酰胺成功转化为含三烯杂环的过程。

  DOI：

  10.1055/s-2008-1078169
• 作为产物：
  描述：

  4-乙炔-2,2-二甲基噁唑啉-3-羧酸叔丁酯 、 碘甲烷 在 正丁基锂 作用下， 以100%的产率得到Tert-butyl 2,2-dimethyl-4-prop-1-ynyl-1,3-oxazolidine-3-carboxylate
  参考文献：
  名称：

  Rhodium(I)-Catalyzed Cycloisomerization Reaction of Yne-Allenamides: An Approach to Cyclic Enamides

  摘要：

  在本文中，我们展示了通过铑（I）催化的环异构化反应将炔基烯酰胺成功转化为含三烯杂环的过程。

  DOI：

  10.1055/s-2008-1078169

文献信息

• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。
• 2-AMINOOXAZOLINES AS TAAR1 LIGANDS
  申请人：Galley Guido

  公开号：US20100120864A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X，Y，R1，R2和n如本文所定义，或其药学适宜的酸加盐。本发明还涉及含有此类化合物的制药组合物，以及用于治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍，应激相关障碍，精神疾病，精神分裂症，神经疾病，帕金森病，神经退行性疾病，阿尔茨海默病，癫痫，偏头痛，物质滥用和代谢性疾病，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收障碍，体温稳态障碍和功能障碍，睡眠和生物钟节律障碍以及心血管疾病。
• Rhodium(I)-Catalyzed Cycloisomerization Reaction of Yne-Allenamides: An Approach to Cyclic Enamides
  作者：Kay Brummond、Bingli Yan

  DOI：10.1055/s-2008-1078169

  日期：——

  In this paper, we demonstrate a successful conversion of alkynyl allenamides to triene-containing heterocycles via a rhodium(I)-catalyzed cycloisomerization reaction.

  在本文中，我们展示了通过铑（I）催化的环异构化反应将炔基烯酰胺成功转化为含三烯杂环的过程。